Paragon Therapeutics
Tracked across 2 events · 37 articles · First seen Jul 21, 2025 · Last active Jul 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Paragon Therapeutics is facing a class action lawsuit for allegedly providing misleading statements regarding its lead cell therapy candidate drug, deramiocel, which led to a significant stock price decline after the United States — Food and Drug Administration denied its Biologics License Application.
Jul 21, 2025 · 31 articles
Regulatory
Impact: Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will convene a meeting to discuss its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. This is a significant step towards potential market approval for their lead product candidate.
Jun 26, 2026 · 6 articles
100
Paragon Therapeutics announced advisory meeting United States — Food and Drug AdministrationCapricor Deramiocel FDA...
ERGEN INTELLIGENCE
Track Paragon Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard